A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC
A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC
Not yet recruiting · NCT07038460 · Registry updated 2025-06-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC | Resectable Non-small Cell Lung Cancer | Not yet recruiting | Phase 2 | 2025-06-26 | NCT07038460 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Wen-zhao ZHONG | 6 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Affiliated Cancer Hospital and Institute of Guangzhou Medical Univercity | Guangzhou | China | 1 |
| Guangdong Province People's Hospital | Guangzhou | China | 3 |
| Hunan Cancer Hospital | Changsha | China | 87 |
| Sun Yet-Sen University Cancer Center | Guangzhou | China | 1 |
| The Second Affiliated Hospital Zhejiang University School of Medicine | Hangzhou | China | 22 |
| Xiangya Hospital Central South University | Changsha | China | 27 |